platinum

Summary

Summary: Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".

Top Publications

  1. ncbi Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis
    Junjie Wu
    National Ministry of Education Key Laboratory of Contemporary Anthropology and State Key Laboratory of Genetic Engineering, School of Life Sciences, Changhai Hospital of Shanghai, Shanghai, China
    Clin Cancer Res 18:3972-81. 2012
  2. ncbi Pd-Pt bimetallic nanodendrites with high activity for oxygen reduction
    Byungkwon Lim
    Department of Biomedical Engineering, Washington University, St Louis, MO 63130, USA
    Science 324:1302-5. 2009
  3. ncbi Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
    Robert E Bristow
    Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD 21287 1248, USA
    J Clin Oncol 20:1248-59. 2002
  4. ncbi Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum
    Wei Yu Liao
    Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    J Thorac Oncol 7:973-81. 2012
  5. ncbi Gold and platinum catalysis--a convenient tool for generating molecular complexity
    Alois Fürstner
    Max Planck Institut fur Kohlenforschung, D 45470 Mulheim Ruhr, Germany
    Chem Soc Rev 38:3208-21. 2009
  6. ncbi The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J Wheate
    Strathclyde Institute of Pharmacy, and Biomedical Sciences, University of Strathclyde, John Arbuthnott Building, 27 Taylor Street, Glasgow, UK G4 0NR
    Dalton Trans 39:8113-27. 2010
  7. ncbi Cisplatin and platinum drugs at the molecular level. (Review)
    Teni Boulikas
    Regulon, Inc, Mountain View, CA 94043, USA
    Oncol Rep 10:1663-82. 2003
  8. ncbi Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic concentrations
    Helge Gehrke
    Department of Food Chemistry and Toxicology, University of Vienna, Vienna, Austria
    Arch Toxicol 85:799-812. 2011
  9. ncbi Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
    Eric Pujade-Lauraine
    University Paris Descartes, Assistance Publique Hopitaux de Paris, Hopital Hotel Dieu, Paris, France
    J Clin Oncol 28:3323-9. 2010
  10. ncbi Direct cellular responses to platinum-induced DNA damage
    Yongwon Jung
    Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 4307, USA
    Chem Rev 107:1387-407. 2007

Detail Information

Publications346 found, 100 shown here

  1. ncbi Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis
    Junjie Wu
    National Ministry of Education Key Laboratory of Contemporary Anthropology and State Key Laboratory of Genetic Engineering, School of Life Sciences, Changhai Hospital of Shanghai, Shanghai, China
    Clin Cancer Res 18:3972-81. 2012
    ..repair cross-complementing group 1 (XRCC1) gene polymorphisms (Arg399Gln and Arg194Trp) and clinical outcome of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)...
  2. ncbi Pd-Pt bimetallic nanodendrites with high activity for oxygen reduction
    Byungkwon Lim
    Department of Biomedical Engineering, Washington University, St Louis, MO 63130, USA
    Science 324:1302-5. 2009
    ..The Pd-Pt nanodendrites were two and a half times more active on the basis of equivalent Pt mass for the ORR than the state-of-the-art Pt/C catalyst and five times more active than the first-generation supportless Pt-black catalyst...
  3. ncbi Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
    Robert E Bristow
    Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD 21287 1248, USA
    J Clin Oncol 20:1248-59. 2002
    To evaluate the relative effect of percent maximal cytoreductive surgery and other prognostic variables on survival among cohorts of patients with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy.
  4. ncbi Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum
    Wei Yu Liao
    Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    J Thorac Oncol 7:973-81. 2012
    Elevated DNA-repair capacity has been related to chemoresistance of platinum doublet chemotherapy in non-small-cell lung cancer (NSCLC)...
  5. ncbi Gold and platinum catalysis--a convenient tool for generating molecular complexity
    Alois Fürstner
    Max Planck Institut fur Kohlenforschung, D 45470 Mulheim Ruhr, Germany
    Chem Soc Rev 38:3208-21. 2009
    ..with the essence of pi-acid catalysis, in particular with reactions or reaction cascades effected by gold and platinum complexes...
  6. ncbi The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J Wheate
    Strathclyde Institute of Pharmacy, and Biomedical Sciences, University of Strathclyde, John Arbuthnott Building, 27 Taylor Street, Glasgow, UK G4 0NR
    Dalton Trans 39:8113-27. 2010
    ..Over the last 30 years, 23 other platinum-based drugs have entered clinical trials with only two (carboplatin and oxaliplatin) of these gaining ..
  7. ncbi Cisplatin and platinum drugs at the molecular level. (Review)
    Teni Boulikas
    Regulon, Inc, Mountain View, CA 94043, USA
    Oncol Rep 10:1663-82. 2003
    Over twenty years of intensive work toward improvement of cisplatin, and with hundreds of platinum drugs tested, has resulted in the introduction of the widely used carboplatin and of oxaliplatin used only for a very narrow spectrum of ..
  8. ncbi Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic concentrations
    Helge Gehrke
    Department of Food Chemistry and Toxicology, University of Vienna, Vienna, Austria
    Arch Toxicol 85:799-812. 2011
    Three differently sized, highly dispersed platinum nanoparticle (Pt-NP) preparations were generated by supercritical fluid reactive deposition (SFRD) and deposited on a β-cyclodextrin matrix...
  9. ncbi Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
    Eric Pujade-Lauraine
    University Paris Descartes, Assistance Publique Hopitaux de Paris, Hopital Hotel Dieu, Paris, France
    J Clin Oncol 28:3323-9. 2010
    ..the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-sensitive relapsed/recurrent ovarian cancer (ROC).
  10. ncbi Direct cellular responses to platinum-induced DNA damage
    Yongwon Jung
    Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 4307, USA
    Chem Rev 107:1387-407. 2007
  11. pmc Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients
    Ji Ye Yin
    Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China
    PLoS ONE 7:e38150. 2012
    To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients.
  12. ncbi Management strategies for recurrent platinum-resistant ovarian cancer
    R Wendel Naumann
    Carolinas Medical Center, Charlotte, NC, USA
    Drugs 71:1397-412. 2011
    Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge...
  13. ncbi Autonomous movement of platinum-loaded stomatocytes
    Daniela A Wilson
    Radboud University Nijmegen, Institute for Molecules and Materials, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands
    Nat Chem 4:268-74. 2012
    ..to generate autonomous movement of the polymer stomatocytes by selectively entrapping catalytically active platinum nanoparticles within their nanocavities and subsequently using catalysis as a driving force for movement...
  14. pmc SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer
    Whasun Lim
    WCU Biomodulation Major, Department of Agricultural Biotechnology, Seoul National University, Gwanak Gu, Seoul, Korea
    PLoS ONE 7:e49869. 2012
    ..Strong expression of SERPINB3 protein was a prognostic factor for platinum resistance (adjusted OR; odds ratio, 5.94; 95% Confidence Limits, 1.21-29...
  15. ncbi Templated photocatalytic synthesis of well-defined platinum hollow nanostructures with enhanced catalytic performance for methanol oxidation
    Feng Bai
    Key Laboratory for Special Functional Materials of the Ministry of Education, Henan University, Kaifeng 475004, People s Republic of China
    Nano Lett 11:3759-62. 2011
    ..Here we report a facile photocatalytic process to synthesize and tune hollow platinum (Pt) nanostructures...
  16. ncbi Platinum-gold nanoparticles: a highly active bifunctional electrocatalyst for rechargeable lithium-air batteries
    Yi Chun Lu
    Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    J Am Chem Soc 132:12170-1. 2010
    ..It is hypothesized that PtAu NPs exhibit bifunctional catalytic activity, having surface Au and Pt atoms primarily responsible for ORR and OER kinetics in Li-O(2) cells, respectively...
  17. ncbi Effects of a potent antioxidant, platinum nanoparticle, on the lifespan of Caenorhabditis elegans
    Juewon Kim
    Department of Integrated Biosciences, University of Tokyo, Chiba, Japan
    Mech Ageing Dev 129:322-31. 2008
    We have shown that platinum nanoparticles (nano-Pt) are a superoxide dismutase (SOD)/catalase mimetic. Various data have shown extension of the Caenorhabditis elegans lifespan by antioxidant treatment...
  18. ncbi A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells
    James Turkson
    Molecular Oncology and Drug Discovery Programs, H Lee Moffitt Cancer Center and Research Institute, Orlando, FL 32826, USA
    J Biol Chem 280:32979-88. 2005
    ..Of these, a novel platinum (IV) compound, IS3 295, interacted with Stat3 and inhibited its binding to specific DNA-response elements...
  19. ncbi Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review
    Mark Murphy
    National Institute for Cellular Biotechnology, Dublin City University, Ireland
    Drug Resist Updat 14:177-90. 2011
    b>Platinum-based chemotherapy is the standard of care for ovarian cancer and non-small cell lung cancer (NSCLC). However, resistance to platinum agents invariably develops...
  20. ncbi Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair
    Ji Ye Yin
    Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiang Ya Hospital, Central South University, Changsha, Hunan, PR China
    Clin Cancer Res 17:4600-9. 2011
    ..The purpose of this study is to test the hypothesis that eIF3a may regulate the expression of DNA repair proteins which, in turn, affects response of lung cancer patients to treatments by DNA-damaging anticancer drugs...
  21. ncbi DNA damage and p53-mediated growth arrest in human cells treated with platinum nanoparticles
    P V AshaRani
    Department of Chemistry, Faculty of Science, 3 Science Drive 3, National University of Singapore, Singapore
    Nanomedicine (Lond) 5:51-64. 2010
    b>Platinum-based therapeutic agents are widely used in medicine. Thus, a thorough understanding of their mechanism of action in cells is warranted. This study investigates the uptake and bioactivity (e.g...
  22. ncbi Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells
    Goli Samimi
    Department of Medicine, University of California San Diego, La Jolla, California, 92093 0058, USA
    Clin Cancer Res 10:4661-9. 2004
    ..The goal of this study was to determine the effect of small changes in ATP7A expression on the pharmacodynamics of cisplatin, carboplatin, and oxaliplatin in human ovarian carcinoma cells...
  23. ncbi Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis
    Nyree Crawford
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, UK
    Apoptosis 16:311-20. 2011
    ..inhibitor of pro-survival BCL-2 family proteins including MCL-1, decreases cell viability irrespective of platinum resistance status across a panel of cell lines selected for oxaliplatin resistance...
  24. ncbi Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity
    D J Gallagher
    Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, USA
    Ann Oncol 22:1127-32. 2011
    ..To further explore this, we examined the impact of prognostic factors on disease-free survival (DFS) and overall survival (OS) in patients with known BRCA mutation status...
  25. ncbi SOD/catalase mimetic platinum nanoparticles inhibit heat-induced apoptosis in human lymphoma U937 and HH cells
    Yoko Yoshihisa
    Department of Dermatology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
    Free Radic Res 45:326-35. 2011
    b>Platinum nanoparticles (Pt-NPs) are known to possess anti-tumouric activity and the ability to scavenge superoxides and peroxides indicating that they can act as superoxide dismutase (SOD)/catalase mimetics...
  26. pmc Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants
    Peter H O'Donnell
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    Pharmacogenet Genomics 20:327-37. 2010
    Clinical studies show that Asians (ASN) are more susceptible to toxicities associated with platinum-containing regimens...
  27. ncbi Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer
    Pierluigi Benedetti Panici
    Department of Obstetrics and Gynecology, University of Rome La Sapienza, Viale del Policlinico, 155, 00161, Rome, Italy
    Ann Surg Oncol 14:1136-42. 2007
    ..The aim of this prospective observational trial was to analyze the role of SCR in patients with platinum-sensitive ovarian cancer.
  28. ncbi Strong neuroprotection with a novel platinum nanoparticle against ischemic stroke- and tissue plasminogen activator-related brain damages in mice
    M Takamiya
    Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700 8558, Japan
    Neuroscience 221:47-55. 2012
    ..The platinum nanoparticle (nPt) is a novel ROS scavenger, and thus we examined the clinical and neuroprotective effects of nPt ..
  29. ncbi Kinetic analysis of superoxide anion radical-scavenging and hydroxyl radical-scavenging activities of platinum nanoparticles
    Takeki Hamasaki
    Department of Genetic Resources Technology, Faculty of Agriculture, Kyushu University, Hakozaki, Higashi ku, Fukuoka 812 8581, Japan
    Langmuir 24:7354-64. 2008
    ..These findings suggest that Pt nps may be a new type of antioxidant capable of circumventing the paradoxical effects of conventional antioxidants...
  30. ncbi Self-propelled nanotools
    Alexander A Solovev
    Institute for Integrative Nanosciences, IFW Dresden, Helmholtzstrasse 20, D 01069 Dresden, Germany
    ACS Nano 6:1751-6. 2012
    ..Our observations suggest that shape and asymmetry can be utilized to direct the motion of catalytic nanotubes and enable mechanized functions at the nanoscale...
  31. pmc Mechanistic basis for overcoming platinum resistance using copper chelating agents
    Zheng D Liang
    Department of Molecular Pathology, Unit 951, Room 2SCR4 3025, The University of Texas MD Anderson Cancer Center, 7435 Fannin Blvd, Houston, TX 77054, USA
    Mol Cancer Ther 11:2483-94. 2012
    b>Platinum-based antitumor agents are widely used in cancer chemotherapy. Drug resistance is a major obstacle to the successful use of these agents because once drug resistance develops, other effective treatment options are limited...
  32. ncbi Targeting and delivery of platinum-based anticancer drugs
    Xiaoyong Wang
    State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing 210093, P R China
    Chem Soc Rev 42:202-24. 2013
    b>Platinum-based anticancer drugs occupy a crucial role in the treatment of various malignant tumours. However, the efficacy and applicability of platinum drugs are heavily restricted by severe systemic toxicities and drug resistance...
  33. ncbi The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer
    Ioannis Gioulbasanis
    Department of Medical Oncology, University Hospital of Larissa, Greece
    Lung Cancer 77:383-8. 2012
    ..The aim of this study was to assess the predictive value of baseline GPS in terms of toxicity and response in lung cancer patients treated with platinum-based chemotherapy.
  34. ncbi [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer]
    Chong an Xu
    Department of Medical Oncology, The Fourth Affiliated Hospital, China Medical University, Shenyang 110032, China
    Zhongguo Fei Ai Za Zhi 14:912-7. 2011
    DNA repair gene polymorphisms can be used to predict the sensitivity of platinum-based chemotherapy. Thus, such polymorphisms are important for the individual treatment of non-small cell lung cancer (NSCLC)...
  35. pmc Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer
    Angela J Ziebarth
    Departments of Obstetrics and Gynecology, Radiation Oncology, and Pathology, University of Alabama at Birmingham, Birmingham, AL 35249, USA
    Clin Cancer Res 19:170-82. 2013
    ..Our objective was to evaluate the effects and mechanisms of targeting endoglin in ovarian cancer...
  36. pmc Platinum-based chemotherapy for variant castrate-resistant prostate cancer
    Ana M Aparicio
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 3721, USA
    Clin Cancer Res 19:3621-30. 2013
    ..We sought to determine the efficacy of platinum-based chemotherapy in patients meeting at least one of seven prospectively defined "anaplastic" clinical criteria,..
  37. ncbi Platinum nanoparticle ensemble-on-graphene hybrid nanosheet: one-pot, rapid synthesis, and used as new electrode material for electrochemical sensing
    Shaojun Guo
    State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, Jilin, China
    ACS Nano 4:3959-68. 2010
    ..Therefore, PNEGHNs may be an attractive robust and advanced hybrid electrode material with great promise for electrochemical sensors and biosensors design...
  38. ncbi Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal
    Rumona Dickson
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Pharmacoeconomics 29:1051-62. 2011
    ..with non-small cell lung cancer (NSCLC) and stable disease following previous treatment with four cycles of platinum-containing therapy...
  39. ncbi CoS supersedes Pt as efficient electrocatalyst for triiodide reduction in dye-sensitized solar cells
    Mingkui Wang
    Laboratory for Photonics and Interfaces, Swiss Federal Institute of Technology, CH 1015, Lausanne, Switzerland
    J Am Chem Soc 131:15976-7. 2009
    ..This is expected to have an important practical consequence on the production of flexible low-cost and lightweight thin film DSC devices based on the plastic matrix...
  40. ncbi Mesoporous silica as a membrane for ultra-thin implantable direct glucose fuel cells
    Tushar Sharma
    Department of Biomedical Engineering, University of Texas at Austin, Austin, TX 78712, USA
    Lab Chip 11:2460-5. 2011
    ..We report development of an implantable device with a platinum thin-film (thickness: 25 nm) deposited on silicon substrate (500 μm) to serve as the anode, and graphene pressed ..
  41. ncbi In vitro and in vivo studies of FePt nanoparticles for dual modal CT/MRI molecular imaging
    Shang Wei Chou
    Department of Chemistry, National Taiwan Normal University, Taipei 11677, Taiwan
    J Am Chem Soc 132:13270-8. 2010
    ..The 12 nm-FePt outperformed 3 nm-FePt in both imaging modalities. These results indicate the potential of FePt nanoparticles to serve as novel multimodal molecular imaging contrast agents in clinical settings...
  42. ncbi Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy
    Hong Tae Kim
    Department of Biological Science, Sungkyunkwan University, Suwon, Korea
    J Clin Oncol 26:5972-9. 2008
    To determine whether germ-line variations in BRCA1 affect outcome in non-small-cell lung cancer (NSCLC) patients treated with platinum combination chemotherapy.
  43. ncbi Quantitative evaluation of susceptibility and shielding effects of nitinol, platinum, cobalt-alloy, and stainless steel stents
    Yi Wang
    Department of Radiology, Weill Medical College of Cornell University, New York, New York, USA
    Magn Reson Med 49:972-6. 2003
    ..Susceptibility induced signal loss was negligible (<1%) for nonstainless-steel (nitinol, platinum, and cobalt-alloy) stents and totally destructive (100%) for the stainless steel stent...
  44. ncbi Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin
    Bernd Liedert
    Institute of Cell Biology, University of Essen, Germany
    J Invest Dermatol 121:172-6. 2003
    ..transporter) (MRP2/ABCC2) in cisplatin resistance of melanoma, the expression of this protein was analyzed in the platinum drug-resistant cell line MeWo CIS 1...
  45. ncbi Comparison of the toxicity of silver, gold and platinum nanoparticles in developing zebrafish embryos
    P V AshaRani
    Department of Chemistry, National University of Singapore, Singapore
    Nanotoxicology 5:43-54. 2011
    ..Toxicity assays of silver, gold, and platinum nanoparticles, using zebrafish embryos to study their developmental effects were carried out...
  46. ncbi Synthesis of platinum nanowire networks using a soft template
    Yujiang Song
    Advanced Materials Laboratory, Sandia National Laboratories, Albuquerque, NM 87106, USA
    Nano Lett 7:3650-5. 2007
    b>Platinum nanowire networks have been synthesized by chemical reduction of a platinum complex using sodium borohydride in the presence of a soft template formed by cetyltrimethylammonium bromide in a two-phase water-chloroform system...
  47. pmc Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads
    Shanta Dhar
    Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    J Am Chem Soc 131:14652-3. 2009
    ..derivatized with a cisplatin prodrug, and the resulting DNA-Au NP conjugates were used to internalize multiple platinum centers...
  48. ncbi Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity
    Hiromu Katsuda
    Department of Medicinal Informatics, Graduate School of Medical Science, Kanazawa University, 13 1 Takara machi, Kanazawa 920 8641, Japan
    Biol Pharm Bull 33:1867-71. 2010
    ..Cimetidine (1 mM) also did not influence platinum concentration in the cells, regardless of whether the organic cation transporter 2 (OCT2) was expressed...
  49. pmc Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers
    Dana Ziliak
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Transl Res 157:265-72. 2011
    ..could offer significant benefit to patients as a means of potentially reducing morbidity associated with platinum-based chemotherapy...
  50. ncbi Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin
    E E M Brouwers
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    Anal Bioanal Chem 391:577-85. 2008
    We present a highly sensitive method for the determination of platinum (Pt) in DNA extracts of peripheral blood mononuclear cells (PBMCs) and tissue samples from patients treated with cisplatin...
  51. ncbi Glucose biosensor based on immobilization of glucose oxidase in platinum nanoparticles/graphene/chitosan nanocomposite film
    Hong Wu
    Pacific Northwest National Laboratory, Richland, WA 99352, USA
    Talanta 80:403-6. 2009
    ..The hybrid nanocomposite glucose sensor provides new opportunity for clinical diagnosis and point-of-care applications...
  52. ncbi Nanocrystalline carbonate-apatites: role of Ca/P ratio on the upload and release of anticancer platinum bisphosphonates
    Michele Iafisco
    Dipartimento di Chimica G Ciamician, Alma Mater Studiorum, Universita di Bologna, Via Selmi 2, 40126 Bologna, Italy
    Nanoscale 4:206-17. 2012
    ..In order to assess how the Ca/P ratio can influence the adsorption and release of anticancer platinum-bisphosphonate complexes, two kinds of apatite nanocrystals having different Ca/P ratios but similar morphologies,..
  53. ncbi Adsorption of platinum (IV), palladium (II) and gold (III) from aqueous solutions onto L-lysine modified crosslinked chitosan resin
    Kensuke Fujiwara
    Department of Chemistry and Chemical Engineering, Graduate School of Natural Science and Technology, Kakuma, Kanazawa University, Kanazawa 920 1192, Japan
    J Hazard Mater 146:39-50. 2007
    ..The desorption studies were carried out using various reagents. The maximum percent desorption of precious metal ions were obtained when the reagent 0.7 M thiourea-2 M HCl was used...
  54. ncbi Platinum group elements in the environment and their health risk
    Khaiwal Ravindra
    Micro and Trace Analysis Centre, University of Antwerp, Universiteitsplein 1, Antwerp B 2610, Belgium
    Sci Total Environ 318:1-43. 2004
    Accumulation of platinum group elements (PGEs) in the environment has been increased over the time...
  55. ncbi Platinum nanoparticle is a useful scavenger of superoxide anion and hydrogen peroxide
    Masashi Kajita
    Department of Integrated Biosciences, Graduate School of Frontier Sciences, University of Tokyo, Chiba, Japan
    Free Radic Res 41:615-26. 2007
    Bimetallic nanoparticles consisting of gold and platinum were prepared by a citrate reduction method and complementarily stabilized with pectin (CP-Au/Pt). The percent mole ratio of platinum was varied from 0 to 100%...
  56. pmc Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
    Neil Johnson
    Departments of Medical Oncology, Radiation Oncology, and Cancer Biology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215
    Proc Natl Acad Sci U S A 110:17041-6. 2013
    ..occur in clinical samples of BRCA1-mutated recurrent ovarian carcinomas that have developed resistance to platinum. These results provide evidence for a two-event mechanism by which BRCA1-mutant tumors acquire anticancer therapy ..
  57. ncbi Synthesis and oxygen reduction activity of shape-controlled Pt(3)Ni nanopolyhedra
    Jun Zhang
    Department of Chemistry, State University of New York at Binghamton, Binghamton, New York 13902, USA
    Nano Lett 10:638-44. 2010
    b>Platinum-based alloys have been extensively shown to be effective catalysts for oxygen reduction reaction (ORR) in proton exchange membrane fuel cells (PEMFCs). Most of these catalysts are nanoparticles without shape control...
  58. ncbi Shape and composition-controlled platinum alloy nanocrystals using carbon monoxide as reducing agent
    Jianbo Wu
    Department of Chemical Engineering, University of Rochester, Rochester, New York 14627, USA
    Nano Lett 11:798-802. 2011
    ..9 V are 0.85 mA/cm(2)(Pt) for the nanocubes, and 1.26 mA/cm(2)(Pt) for the nanooctahedra. The ORR mass activity of the octahedral Pt(3)Ni catalyst reaches 0.44 A/mg(Pt)...
  59. ncbi HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance
    Kanokwan Iramaneerat
    Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Int J Gynecol Cancer 21:51-7. 2011
    In general, ovarian clear cell carcinoma (OCCC) has a history of poor response to standard platinum-based chemotherapy regimens, and advanced cases have short survival periods...
  60. ncbi Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin
    J G Morrison
    Department of Clinical Pharmacokinetics and Drug Metabolism, Sanofi Synthelabo, Alnwlick Research Centre, Northumberland, UK
    J Pharm Biomed Anal 24:1-10. 2000
    ELOXATIN (Oxaliplatin) is a novel platinum containing anti-cancer agent with a diaminocyclohexane carrier ligand which has been approved in several major European countries...
  61. ncbi Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 118:386-91. 2012
    In a randomized controlled trial (RCT) of patients with recurrent, platinum-sensitive ovarian cancer, the combination weekly docetaxel and carboplatin was associated a with progression-free survival (PFS) of 13.7 months compared with 8...
  62. ncbi Biosynthesis of platinum nanoparticles by Escherichia coli MC4100: can such nanoparticles exhibit intrinsic surface enantioselectivity?
    Gary Attard
    School of Chemistry, Cardiff University, Cardiff, United Kingdom
    Langmuir 28:5267-74. 2012
    The biomanufacture of two types of platinum bionanoparticle (bioNP) using Escherichia coli MC4100(1% and 20% by mass metal loading) together with a method for both liberating the nanoparticles (NPs) from the bacterial layer and their ..
  63. ncbi Histologic evaluation of platinum coil embolization in an aneurysm model in rabbits
    D F Kallmes
    Department of Radiology, University of Virginia Health Services, Charlottesville 22908, USA
    Radiology 213:217-22. 1999
    To characterize the histologic response to platinum coil embolization by using a rabbit aneurysm model.
  64. ncbi Control over the branched structures of platinum nanocrystals for electrocatalytic applications
    Liang Ma
    Hefei National Laboratory for Physical Sciences at the Microscale, University of Science and Technology of China, Hefei, Anhui 230026, PR China
    ACS Nano 6:9797-806. 2012
    ..It is anticipated that this work will open a door to design more complex nanostructures and to achieve specific functions for various applications...
  65. pmc Transcription inhibition by platinum-DNA cross-links in live mammalian cells
    Wee Han Ang
    Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    J Am Chem Soc 132:7429-35. 2010
    ..Pt-DNA cross-links in live mammalian cells to enhance our understanding of the mechanism of action of platinum-based anticancer drugs...
  66. ncbi Glucose biosensors based on platinum nanoparticles-deposited carbon nanotubes in sol-gel chitosan/silica hybrid
    Xinhuang Kang
    School of Chemistry and Chemical Engineering, Sun Yat Sen University, Guangzhou 510275, PR China
    Talanta 74:879-86. 2008
    ..Subsequently, the novel biosensor was applied for the determination of glucose in human serum sample, and good recovery was obtained (in the range of 95-104%)...
  67. ncbi Fluorescent-magnetic hybrid nanoparticles induce a dose-dependent increase in proinflammatory response in lung cells in vitro correlated with intracellular localization
    Andrea D Lehmann
    Institute of Anatomy, University of Bern, Bern 3012, Switzerland
    Small 6:753-62. 2010
    Iron-platinum nanoparticles embedded in a poly(methacrylic acid) (PMA) polymer shell and fluorescently labeled with the dye ATTO 590 (FePt-PMA-ATTO-2%) are investigated in terms of their intracellular localization in lung cells and ..
  68. ncbi Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents
    Roberta Turci
    Laboratory of Environmental Hygiene and Industrial Toxicology, Salvatore Maugeri Foundation, via Ferrata 89, 27100 Pavia, Italy
    Toxicol Lett 134:57-64. 2002
    ..Urinary platinum (Pt) was also detected using inductively coupled plasma-mass spectrometry (ICP-MS)...
  69. ncbi Controlled growth of platinum nanoparticles on strontium titanate nanocubes by atomic layer deposition
    Steven T Christensen
    Department of Materials Science and Engineering Northwestern University Evanston, IL 60208 3108, USA
    Small 5:750-7. 2009
    ..X-ray absorption spectroscopy shows a progression from platinum(II) oxide to metallic platinum and a decrease in Pt--O bonding with an increase in Pt--Pt bonding as the number ..
  70. ncbi Three-dimensional time-of-flight (3D TOF) magnetic resonance angiography (MRA) and contrast-enhanced MRA of intracranial aneurysms treated with platinum coils
    J Wikstrom
    Department of Radiology, Uppsala University Hospital, Uppsala, Sweden
    Acta Radiol 49:190-6. 2008
    ..CE-MRA) is less prone to flow-related signal intensity loss than three-dimensional time-of-flight (3D TOF) MRA and may therefore be more sensitive for detection of residual patency in platinum coil-treated intracranial aneurysms.
  71. ncbi Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience
    J Alexandre
    Universite Paris Descartes, Hotel Dieu, France
    Ann Oncol 21:2377-81. 2010
    ....
  72. pmc Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy
    Yafei Li
    Department of Health Sciences Research, Rochester, Minnesota, USA
    Clin Cancer Res 17:3830-40. 2011
    ....
  73. ncbi Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia
    Christopher W Lee
    BC Cancer Agency Fraser Valley Centre, 13750 96th Avenue, Surrey, British Columbia, Canada V3V 1Z2
    Lung Cancer 64:308-13. 2009
    ..The impact of these platinum-based regimens is assessed in this review of practice in the province of British Columbia...
  74. ncbi Amine-assisted synthesis of concave polyhedral platinum nanocrystals having {411} high-index facets
    Xiaoqing Huang
    State Key Laboratory for Physical Chemistry of Solid Surfaces and Department of Chemistry, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China
    J Am Chem Soc 133:4718-21. 2011
    ..The presence of high-index {411} exposed facets endows the concave Pt nanocrystals with excellent electrocatalytic activity in the oxidation of both formic acid and ethanol...
  75. ncbi Facile synthesis of highly faceted multioctahedral Pt nanocrystals through controlled overgrowth
    Byungkwon Lim
    Department of Biomedical Engineering, Washington University, St Louis, Missouri 63130, USA
    Nano Lett 8:4043-7. 2008
    ..These multioctahedral Pt nanocrystals were tested as electrocatalysts for the oxygen reduction reaction in a proton exchange membrane fuel cell and exhibited improved specific activity and durability compared to commercial Pt/C catalyst...
  76. ncbi Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer
    G K Siddiqui
    Department of Obstetrivs and Gynaecology, Royal Free and University College Medical School, London, UK
    Angiogenesis 14:155-61. 2011
    For patients with epithelial ovarian cancer (EOC) cytoreduction, with a combination of taxane and platinum, is the standard of care...
  77. ncbi Synthesis, structural characterization, and quadruplex DNA binding studies of platinum(II)-terpyridine complexes
    Kogularamanan Suntharalingam
    Department of Chemistry, Imperial College London, London SW7 2AZ, UK
    Inorg Chem 48:9427-35. 2009
    Three new substituted terpyridine ligands and their corresponding platinum(II) complexes have been prepared and fully characterized (including the X-ray crystal structures of two of the complexes)...
  78. ncbi Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients
    Jie Yin
    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    J Cell Mol Med 16:337-48. 2012
    Early detection of resistance to platinum-based therapy is critical for improving the treatment of ovarian cancers...
  79. ncbi Selective and sensitive electrochemical detection of glucose in neutral solution using platinum-lead alloy nanoparticle/carbon nanotube nanocomposites
    Hui Fang Cui
    Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore 117543
    Anal Chim Acta 594:175-83. 2007
    ..The Nafion coating lowered the detection limit by reducing the background noise, while the second layer of PtPbNPs restored the sensitivity to the level before Nafion coating...
  80. ncbi Mathematical modelling of physicochemical reactions and transport processes occurring around a platinum cathode during the electrochemical treatment of tumours
    E Nilsson
    Department of Chemical Engineering and Technology, Applied Electrochemistry, Royal Institute of Technology KTH, Stockholm, Sweden
    Bioelectrochemistry 53:213-24. 2001
    ..A simplified mathematical model of the physicochemical processes, occurring around a spherical platinum cathode during EChT, is developed and visualized in three steps in this paper...
  81. ncbi Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands
    Radim Vrzal
    Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Olomouc, Czech Republic
    J Inorg Biochem 104:1130-2. 2010
    ..The improved cytotoxic effect was demonstrated for the platinum(II) complexes 3 (IC(50)=3.2+/-1.0 microM and 3.2+/-0.6 microM) and 5 (IC(50)=4.0+/-1.0 microM and 4.1+/-1...
  82. pmc Imaging the distribution of individual platinum-based anticancer drug molecules attached to single-wall carbon nanotubes
    Ashwin A Bhirde
    University of Connecticut, Storrs, CT 06269, USA
    Nanomedicine (Lond) 4:763-72. 2009
    ..To image the distribution of drug molecules attached to single-wall carbon nanotubes (SWNTs)...
  83. ncbi Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXU
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 56:264-71. 2010
    The aim of this study was to evaluate the safety and efficacy of the novel platinum chromium TAXUS Element paclitaxel-eluting stent (PES) compared with the TAXUS Express PES (Boston Scientific, Natick, Massachusetts) in treating coronary ..
  84. ncbi Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes
    Saeed Ahmad
    Department of Chemistry, University of Engineering and Technology, Lahore 54890, Pakistan
    Chem Biodivers 7:543-66. 2010
    b>Platinum-based compounds are widely used as chemotherapeutics for the treatment of a variety of cancers. The anticancer activity of cisplatin and other platinum drugs is believed to arise from their interaction with DNA...
  85. pmc Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol
    S Fujiyama
    Third Department of Internal Medicine, Kumamoto University School of Medicine, Honjo, Japan
    Br J Cancer 89:1614-9. 2003
    SM-11355 is a platinum complex developed to treat hepatocellular carcinoma (HCC). It is administered via the hepatic artery, using a carrier, lipiodol, that consists of ethyl esters of iodized poppy seed oil...
  86. ncbi Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1
    Sergio Pecorelli
    University of Brescia, Brescia, Italy
    J Clin Oncol 27:4642-8. 2009
    To assess whether six courses of paclitaxel are effective as consolidation treatment in patients with advanced epithelial ovarian cancer who are in complete response after first-line paclitaxel/platinum-based chemotherapy.
  87. ncbi Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
    Lynn C Hartmann
    Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 11:2149-55. 2005
    Women with advanced epithelial ovarian cancer are routinely treated with platinum-paclitaxel chemotherapy following cytoreductive surgery, yet only approximately 20% achieve long-term disease-free survival...
  88. ncbi Improved planar amperometric nitric oxide sensor based on platinized platinum anode. 1. Experimental results and theory when applied for monitoring NO release from diazeniumdiolate-doped polymeric films
    Youngmi Lee
    Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, MI 48109 1055, USA
    Anal Chem 76:536-44. 2004
    ..The sensor is fabricated using a platinized platinum anode and a Ag/AgCl cathode housed behind a microporous poly(tetrafluoroethylene) (PTFE; Gore-tex) gas-permeable ..
  89. ncbi Electrochemical biosensing platforms using platinum nanoparticles and carbon nanotubes
    Sabahudin Hrapovic
    Biotechnology Research Institute, National Research Council Canada, Montreal, Quebec, Canada H4P 2R2
    Anal Chem 76:1083-8. 2004
    b>Platinum nanoparticles with a diameter of 2-3 nm were prepared and used in combination with single-wall carbon nanotubes (SWCNTs) for fabricating electrochemical sensors with remarkably improved sensitivity toward hydrogen peroxide...
  90. ncbi Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer 115:2119-27. 2009
    ..A study was undertaken to determine recurrence patterns and survival outcomes of stage I uterine papillary serous carcinoma (UPSC) patients...
  91. ncbi Contrast-enhanced MR angiography at 1.5 T after implantation of platinum stents: in vitro and in vivo comparison with conventional stent designs
    Klaus D Hagspiel
    Department of Radiology, Division of Interventional Radiology, University of Virginia Health System, Box 800170, Charlottesville, VA 22908, USA
    AJR Am J Roentgenol 184:288-94. 2005
    ..of our study was to evaluate the in vitro and in vivo 3D contrast-enhanced MR angiography characteristics of a new platinum-based balloon-expandable stent system and compare this system with a variety of competing metallic stents.
  92. ncbi In vitro free radical scavenging activity of platinum nanoparticles
    Aki Watanabe
    Department of Integrated Biosciences, Graduate School of Frontier Sciences, University of Tokyo, Bioscience Building 402, 5 1 5 Kashiwanoha, Kashiwa, Chiba 277 8562, Japan
    Nanotechnology 20:455105. 2009
    A polyacrylic acid (PAA)-protected platinum nanoparticle species (PAA-Pt) was prepared by alcohol reduction of hexachloroplatinate. The PAA-Pt nanoparticles were well dispersed and homogeneous in size with an average diameter of 2.0 +/- 0...
  93. ncbi Adsorption of gold(III), platinum(IV) and palladium(II) onto glycine modified crosslinked chitosan resin
    A Ramesh
    Department of Chemistry and Chemical Engineering, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma, Kanazawa 920 1192, Japan
    Bioresour Technol 99:3801-9. 2008
    ..The modification of glycine on crosslinked chitosan resin (CCR) was studied by Fourier transform infrared spectrometry (FTIR) and scanning electron microscopy (SEM)...
  94. ncbi Cyclometalated platinum(II) complexes as highly sensitive luminescent switch-on probes for practical application in protein staining and cell imaging
    Peng Wu
    Department of Chemistry and Open Laboratory of Chemical Biology, The Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Pokfulam Road, Hong Kong, PR China
    Chemistry 15:3652-6. 2009
    Protein-staining platinum: The luminescent switch-on characteristic of the platinum(II) complex can be utilized for staining a series of proteins in sodium dodecyl sulfate-polyarcylamide gels, to give emissive gel images directly under UV ..
  95. ncbi Synthesis of platinum cubes, polypods, cuboctahedrons, and raspberries assisted by cobalt nanocrystals
    Stephanie I Lim
    Institut Catala de Nanotecnologia, Barcelona, Spain
    Nano Lett 10:964-73. 2010
    The introduction of metallic traces into the synthesis of platinum nanocrystals (Pt NCs) has been investigated as a surfactant-independent means of controlling shape...
  96. pmc Bacterial toxicity/compatibility of platinum nanospheres, nanocuboids and nanoflowers
    Judy Gopal
    Department of Chemistry, National Sun Yat Sen University, Kaohsiung, 70 Lien Hai Road, 80424, Taiwan
    Sci Rep 3:1260. 2013
    ..This is the first study which reports the bacterial toxicity of Pt NPs. The information released from this study is significantly important to future clinical, medical, biological and biomedical applications of Pt NPs...
  97. ncbi Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity
    Horacio Cabral
    Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8656, Japan
    J Control Release 121:146-55. 2007
    ..Herein, polymeric micelles incorporating dichloro(1,2-diamino-cyclohexane)platinum(II) (DACHPt), the oxaliplatin parent complex, were prepared through the polymer-metal complex formation of DACHPt ..
  98. ncbi What do we know about the reduction of Pt(IV) pro-drugs?
    Ezequiel Wexselblatt
    The Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem, Israel
    J Inorg Biochem 117:220-9. 2012
    b>Platinum(IV) pro-drugs are an important class of molecules that might improve the pharmacological properties of the platinum(II) anticancer agents that are currently used in the clinic...
  99. ncbi The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity
    Leticia Cubo
    Universidad Autonoma Madrid, Department of Inorganic Chemistry, Madrid, 28049, Spain
    Dalton Trans 40:344-7. 2011
    ..These results are consistent with more rapid reduction of the Pt(IV) complexes than would be expected based on the reduction potentials, perhaps associated with the trans arrangement of the chlorido ligands...
  100. ncbi Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane
    Chun Wing Yu
    School of Pharmacy, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
    Bioorg Med Chem Lett 16:1686-91. 2006
    A series of platinum complexes derived from integrating demethylcantharidin (DMC) with different isomers of 1,2-diaminocyclohexane (DACH) has been synthesized and found to exhibit superior in vitro anticancer activity against colorectal ..
  101. ncbi Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer
    Meg Perumal
    Comprehensive Cancer Imaging Centre, Department of Cancer and Surgery, Faculty of Medicine, Imperial College London, Hammersmith Hospital, 240 MRC Cyclotron Building, Du Cane Road, London, W12 0NN, UK
    Mol Imaging Biol 14:753-61. 2012
    We evaluated whether 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) could be used as imaging biomarkers of platinum resensitization in ovarian cancer.

Research Grants74

  1. Targeting Inflammation for the Amelioration of Cisplatin-Hearing Loss
    Vickram Ramkumar; Fiscal Year: 2011
    ..Cisplatin is unique among platinum-based chemotherapy by having a broad spectrum of activity against a number of different cancers compared to more ..
  2. CHEMISTRY AND BIOLOGY OF PLATINUM ANTICANCER DRUGS
    Stephen J Lippard; Fiscal Year: 2013
    ..A leading hypothesis is that the selective toxicity of platinum compounds for tumor versus normal cells and their efficacy for specific tissues are a consequence of the ..
  3. Genetic Susceptibility and Biomarkers of Platinum-related Toxicities
    Lois B Travis; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Platinum compounds comprise one of the most widely used and successful groups of cytotoxic drugs worldwide, given their efficacy in a wide spectrum of tumor types. Each year more than 5...
  4. Organic Cation Transporter PMAT: Physiological Function and Role in Drug Disposit
    Joanne Wang; Fiscal Year: 2013
    ..g. biguanide antihyperglycemics, histamine H2 receptor blockers, platinum-based chemotherapeutics etc.) and toxins (e.g...
  5. Molecular Analysis of NeoAdjuvant Platinum in Triple Negative Breast Cancer
    MARK DANIEL contact PEGRAM; Fiscal Year: 2010
    ..Preclinical data suggests that TNBC may be sensitive to platinum-based chemotherapy because of deficiencies in BRCA-associated DNA repair, especially defective homologous ..
  6. Development of Novel Agents Targeting Genome Stability and Maintenance for Treati
    John J Turchi; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Epithelial ovarian cancer (EOC) is uniformly fatal once resistance to platinum based therapy (Pt) is observed...
  7. Cisplatin Resistance mediated by copper export pathways
    Stephen B Howell; Fiscal Year: 2013
    ..The ability of ATP7B to mediate resistance to the platinum (Pt)-containing drugs has now been demonstrated in multiple experimental systems in this and other laboratories, ..
  8. A phase Ib/II study of AZD2171 and radiation for new brain metastases from NSCLC
    APRIL FITZSIMMONS EICHLER; Fiscal Year: 2010
    ..in a randomized phase III study of bevacizumab, a monoclonal antibody against VEFG-A, in combination with platinum-based chemotherapy...
  9. A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
    Daniela Salvemini; Fiscal Year: 2013
    ..g., paclitaxel), platinum-complex (e.g., oxaliplatin), vinca alkaloids (e.g., vincristine) &proteasome-inhibitor (e.g...
  10. Long-Term Non-Enzymatic Glucose Sensors for an Artificial Pancreas
    NATALIE ANN WISNIEWSKI; Fiscal Year: 2013
    ..We will evaluate the glucose sensor performance with and without platinum nanospheres, catalase and other antioxidants over time...
  11. Electromechanical reshaping of tissue
    Brian Wong; Fiscal Year: 2010
    ..In EMR cartilage is bent into a new shape by a jig, platinum needle electrodes are inserted into regions of increased internal stress, and a small current (<25 mA) is ..
  12. In vivo detection and genome-wide location analysis of DNA-adducts
    Stephen B Howell; Fiscal Year: 2013
    ..The expertise of the investigators include knowledge in cancer biology and platinum drug pharmacology (Drs...
  13. UNIVERSITY OF TEXAS SPORE IN LUNG CANCER
    John D Minna; Fiscal Year: 2013
    ..The projects involve: 1. Molecular Signatures for Individualizing Lung Cancer;2. Risk Prediction for Platinum-based Chemotherapy and Radiotherapy Outcome in Non-Small Cell Lung Cancer Patients;3...
  14. Targeting Rad6 Postreplication DNA Repair to Treat Triple Negative Breast Cancer
    Malathy P V Shekhar; Fiscal Year: 2013
    ..In the U.S., there has been a shift to treating TNBCs with platinum (Pt)-based therapies. Pt compounds cause DNA crosslink breaks (ICLs)...
  15. Thiamine Deficiency and Acquired Auditory Neuropathy
    M Charles Liberman; Fiscal Year: 2013
    ..on thiamine supplementation could be safe and effective in reducing the prevalence of hearing loss among infants in the neonatal intensive care unit and among children or adults undergoing anti-cancer therapies with platinum-based drugs.
  16. Antiprogestin therapy for ovarian cancer
    CARLOS MARCELO TELLERIA; Fiscal Year: 2012
    ..As a result, the majority of patients diagnosed with ovarian cancer require surgery followed by platinum-based chemotherapy...
  17. A MICRO-ELECTRODE STUDY OF OXYGEN-BASED FUNCTIONAL CONNECTIVITY
    Lawrence H Snyder; Fiscal Year: 2012
    ..Guided by resting state fMRI scans, we will insert multiple platinum microelectrodes into a macaque brain in order to verify and characterize correlated fluctuations in oxygen ..
  18. Targeting the ERCC1/XPF nuclease for cancer therapy
    John J Turchi; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Platinum based agents (Pt) are the most commonly prescribed chemotherapeutics used in the treatment of solid tumors and are part of the curative treatment regimen for testicular cancer...
  19. Base-selective heavy atom labels for electron microscopy-based DNA sequencing
    F D Toste; Fiscal Year: 2012
    ..and trigold (ZAu = 79) clusters tethered to a group that selectively react with (alkylating reagents) or bind (platinum diamine complexes) purine bases will be explored...
  20. Chemotherapy Near Death: Modifiable Factors and Outcomes in Ovarian Cancer
    Alexi Wright; Fiscal Year: 2013
    ..The overall goals of this project are: a) to examine outcomes of late-line chemotherapy (defined as e2 non- platinum-based regimens) in patients with platinum-resistant ovarian cancer, including whether patients are receiving care ..
  21. Targeting nucleotide excision repair in combination cancer therapy
    John J Turchi; Fiscal Year: 2013
    Abstract First line treatment of ovarian cancer includes combination therapy with a platinum drug (Pt), either cisplatin or carboplatin (1)...
  22. Titanium-gold-based chemotherapeutics for prostate and kidney cancer
    Maria Contel; Fiscal Year: 2013
    ..Metallo-drugs are important tools in current cancer therapy. Platinum-derived drugs, commonly used, have failed in renal and prostate cancers...
  23. A multicenter outpatient trial of a bihormonal bionic pancreas
    Steven J Russell; Fiscal Year: 2013
    ..is built around an iPhone 4S (Apple), which runs our control algorithm and coordinates communication between a G4 Platinum CGM (DexCom) and two (insulin/glucagon) t:slim insulin pumps (Tandem Diabetes Care)...
  24. Sorbents for Toxic-Metal Removal in Pharmaceutical Development and Manufacture
    GIRISH SRINIVAS; Fiscal Year: 2011
    ..This is well established from the known neurotoxicity and cytotoxicity of the anti- cancer agents, cis-platinum, cis-palladium and their analogues, which bind strongly to DNA and block transcription of critical neural enzymes ..
  25. MicroRNAs in Human Ovarian Cancer
    Jin Q Cheng; Fiscal Year: 2013
    ..Debulking surgery followed by platinum-based chemotherapy schemes is considered standard care for these patients...
  26. New Thermal Sensitive Carboplatin Liposome for Cancer
    Robert A Reed; Fiscal Year: 2010
    ..4 million new cases of cancer expected in 2009, over 0.5 million cases could be treated with platinum based therapies...
  27. Targeting Histone Deacetylases with Small Moleule Inhibitors in Ovarian Cancer
    Dineo Khabele; Fiscal Year: 2013
    ..Despite advances in standard platinum-based treatment, new approaches are needed to make a positive impact on this disease...
  28. Equipment for Gross Hall Vivarium
    JEFFREY GOODWIN; Fiscal Year: 2013
    ..Gross Hall, site of the GHARC and proposed Breeding Center, has received LEED Platinum certification, and the proposed Breeding Center Facility would use "green" cage racks (63% more energy efficient);..
  29. Bcl-2 as a Biomarker for Prognosis and Therapy of Head and Neck Cancer
    James W Rocco; Fiscal Year: 2013
    ..After platinum-based concurrent chemoradiation therapy (platinum CRT), a current standard of care having significant morbidity, ..
  30. Role of HDAC6 in platinum resistance of non-small cell lung cancer
    XIAOHONG MARY ZHANG; Fiscal Year: 2013
    ..by applicant): The long-term goal of this project is to elucidate the role of histone deacetylase 6 (HDAC6) in platinum resistance of non-small cell lung cancer (NSCLC)...
  31. Improving Host Response to Implantable Glucose Sensors via Nitric Oxide Release
    Mark H Schoenfisch; Fiscal Year: 2012
    ..this two year, Phase I SBIR the Company aims to: 1) evaluate the foreign body response of Nitricil(tm) coated platinum wires in a rabbit animal model as a function of nitric oxide concentration and release kinetics;2) fabricate four ..
  32. Discovering a Novel Immunophilin to Lower the Toxicity of Cancer Therapeutics
    Mitchell W Mutz; Fiscal Year: 2012
    ..and often dose limiting side effect of mainstay chemotherapeutics including taxanes, bortezomib, vinca alkaloids, platinum complexes, and newly approved therapeutics such as Eribulin...
  33. Cytoskeletal Mechanisms of Endocytosis
    Tatyana Svitkina; Fiscal Year: 2013
    ..Using our special expertise in platinum replica electron microscopy that is most useful for the analysis of the cytoskeletal architecture, we propose to ..
  34. Value of Delivery of Targeted Therapy for Veterans with Advanced Lung Cancer
    Teresa Hayes; Fiscal Year: 2013
    ..conventional treatment has generally been standardized, predetermined, non-individualized protocols of systemic platinum-based chemotherapy...
  35. Mayo Clinic SPORE in Ovarian Cancer
    Scott H Kaufmann; Fiscal Year: 2013
    ..Project 4. "Flavopiridol reverses platinum resistance in ovarian cancer," builds upon work at Mayo showing that flavopiridol combines with cisplatin to ..
  36. Rho GTPases and Neuroprotection Model in Cancer Therapy
    Qun Lu; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Widely-used chemotherapy drugs, such as platinum, exhibit a high level of treatment-associated toxicity including neurotoxicity which is often dose limiting and can be devastating to a patient's ..
  37. Novel biologic markers of treatment resistance in locally advanced cervical carci
    Krishnansu Sujata Tewari; Fiscal Year: 2012
    ..The main treatment modality for these patients is platinum (Pt) chemotherapy in combination with pelvic radiation therapy (CRT)...
  38. Phase 2/3 of Covered Cheatham Platinum Stent for Aortic Wall Injury
    RICHARD ELLIOT RINGEL; Fiscal Year: 2013
    ..Enrollment into the pivotal trial of bare metal Cheatham Platinum Stents (CPS) for use in CoA is ongoing...
  39. Chemotherapy-Induced Painful Neuropathy: Target Genes and Pathway Discovery
    Lauren E Ta; Fiscal Year: 2012
    ..Oxaliplatin is the third-generation of platinum chemotherapeutic drugs that is approved as the first line of treatment for metastatic colorectal cancer...
  40. EFFECTS OF CISPLATIN ON INNER EAR STEM CELLS
    Mark E Warchol; Fiscal Year: 2012
    ..In the proposed studies, we will first determine whether cisplatin causes the formation of 'platinum adducts'in nuclear DNA of avian supporting cells and whether such DNA damage is correlated with the lack of ..
  41. EGFR Mutations in non-Small Cell Lung Cancer
    Bruce E Johnson; Fiscal Year: 2013
    ..have a 2-3 fold greater response and progression-free survival with less toxicity than those treated with platinum-based systemic chemotherapy...
  42. Genetic Determinants of Lung Cancer Survival
    Ping Yang; Fiscal Year: 2012
    ..genetic variations in the human glutathione metabolic system as one of the promising candidates to predict platinum-based treatment outcomes and survival. Six polymorphic DMA markers were tested as proposed...
  43. The Use of Hyperthermia and Copper Chelation to Overcome Cisplatin Resistance
    CHELSEA DAWN LANDON; Fiscal Year: 2013
    ..Our preliminary data show that HT increases cisplatin uptake and platinum-DNA adduct formation in wild type but not in Ctr1-/- cells indicating the involvement of Ctr1 in this synergism...
  44. GENOTOXICITY OF CHROMIUM COMPOUNDS
    Anatoly Zhitkovich; Fiscal Year: 2013
    ..of Cr-damaged DNA is also expected to uncover novel functions of MMR, a key genome maintenance system and a major factor in the clinical efficacy of platinum-based and some other DNA alkylating chemotherapeutic drugs.
  45. RRM1 in the Management of Lung Cancer
    Gerold Bepler; Fiscal Year: 2013
    ..was based on tumoral RRM1 expression (whether or not gemcitabine was used) and ERCC1 expression (whether or not platinum was used). The outcome of patients on the trial was extremely encouraging with a 1-year survival of 59%...
  46. The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
    Robert C Bast; Fiscal Year: 2013
    ..anti-angiogenic therapy;3) observation of a 39% response rate with aflibercept (VEGF-Trap) and docetaxel against platinum-resistant disease;4) detection of response to the AKT inhibitor perifosine in ovarian cancers with PTEN mutations;..
  47. Discovery and Characterization of Methylation Markers
    David Sidransky; Fiscal Year: 2013
    ..bladder cancer specific methylation markers will be used as markers for non-invasive molecular detection approaches, prognostic markers for PT1 tumors, determination of platinum response and as novel targets for therapeutic prevention.
  48. Development of transporter targeted platinum drugs for neuroblastoma
    Richard D Mamelok; Fiscal Year: 2012
    ..Cisplatin, a first generation platinum analog, is first-line therapy in the treatment f NB and together with other drugs can result in cures of the ..
  49. Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer
    Andrew K Godwin; Fiscal Year: 2013
    ..outcomes with contemporary agents such as dasatinib, with or without the front line chemotherapeutic agents, platinum and paclitaxel...
  50. Development of a novel small molecule, UTL-5g, to treat oxaliplatin-induced throm
    Jiajiu Shaw; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Although oxaliplatin is a third-generation platinum drug, it has become the most prescribed amongst all platinum drugs overtaking its predecessors, cisplatin and carboplatin...
  51. Control of the cellular pharmacology of the platinum-containing drugs by CTR1
    Stephen B Howell; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Multiple lines of evidence indicate that the platinum (Pt)-containing drugs can enter cells, be distributed to various subcellular compartments and exported from cells via transporters that evolved to ..
  52. Institute on Aging Clinical Translational Research Building
    Marco Pahor; Fiscal Year: 2010
    ..we propose to construct the IOA-CTRB of 39,500 GSF, a Leadership in Energy and Environmental Desing (LEED) platinum building, which will host the following new shared resources: clinical research assessment facility, biological ..
  53. BIOMEDICAL APPLICATIONS OF EXPANDED PORPHYRINS
    Alan B Watts; Fiscal Year: 2013
    ..By conjugating a Pt anticancer agent to texaphyrin and controlling the nature of the platinum species employed, we expect to produce new drug leads that i) provide for an increased intracellular delivery of ..
  54. MOLECULAR DESIGN OF FILOPODIA, CELL'S SENSORY ORGANELLES
    Tatyana Svitkina; Fiscal Year: 2012
    ..A key element of our research strategy is to obtain high resolution structural information by platinum replica electron microscopy and correlate it with the dynamic behavior of the same cell recorded by advanced ..
  55. EGF receptor, DNA methylation and platinum resistance in ovarian cancer
    SABRINA LEIGH SAMUDIO-RUIZ; Fiscal Year: 2013
    ..to gain a deeper level of understanding of the signaling pathways and mechanisms that govern the development of platinum resistance in ovarian cancer...
  56. Targeting c-MYC Overcomes Temsirolimus and Cisplatin Resistance of Ovarian Cancer
    PABLO ELIAS VIVAS-MEJIA; Fiscal Year: 2013
    ..Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy, relapse occurs in over 70% of patients, resulting in chemoresistant, fatal disease...
  57. Growth Inhibition Induced by Mifepristone in Ovarian Cancer
    Carlos Telleria; Fiscal Year: 2009
    ..Treatment for ovarian cancer generally involves cytoreductive surgery followed by platinum-based chemotherapy, yet the major barrier that this treatment encounters is the development of chemoresistance, ..
  58. Targeted Therapy for Endometrial Cancer
    Kimberly K Leslie; Fiscal Year: 2013
    ..to enhance the number of cells in vulnerable periods of the cell cycle: taxanes are effective for cells in M, and platinum-based compounds and anthracyclines work primarily in S...
  59. Evaluation of Carbon Nanotube Electrodes for Neural Stimulation
    CHARLES BERNARD PARKER; Fiscal Year: 2012
    ..We will compare the performance of CNT electrodes to AIROF and traditional platinum electrodes using quantitative in vitro measurements...
  60. IHC Test for BRCA1 Hereditary Ovarian Cancer
    Jeffrey T Holt; Fiscal Year: 2012
    ..was available and recent data indicates that BRCA hereditary cancers respond to targeted therapies such as cis-platinum and PARP inhibitors...
  61. Signaling Mechanisms Coordinating Cell Fate Determination and Morphogenesis
    Daniel Weinstein; Fiscal Year: 2010
    ..Ctrl has been shown to mediate the uptake of cisplatin, an effective cancer chemotherapy agent, as well as other platinum agents, in yeast, mouse, and human cells...
  62. MECHANISTIC STUDIES ON NEW PLATINUM CLINICAL AGENTS
    Nicholas P Farrell; Fiscal Year: 2012
    ..of this revised renewal proposal is the study of the mechanism of action of a clinically relevant series of platinum-based anticancer agents based on a poly(di/tri)nuclear motif...
  63. Electrodeposited Noble Metal Oxide Neural Electrodes
    Stuart Cogan; Fiscal Year: 2002
    ..is to develop electrodeposition processes suitable for coating a broad range of metal substrates such as platinum, gold, PtIr-alloys, titanium, tungsten, and stainless steel, relevant to most neural recording and stimulating ..
  64. GLUTATHIONE AND RESISTANCE TO CANCER CHEMOTHERAPY
    Owen Griffith; Fiscal Year: 2000
    ..g., melphalan, cyclophosphamide, chlorambucil) and platinum antitumor compounds (e.g. cisplatin, carboplatin) are used to treat a wide range of human malignancies...
  65. A Freeze-Fracture & Etching System for Northwestern Univ
    Mark Johnson; Fiscal Year: 2002
    ..to be purchased is a Cressington CFE Freeze- Fracture Replication System outfitted with low and 45 degree angle platinum/carbon and tantalum/tungsten shadowing sources, two 90 degree carbon backing evaporation guns, two microtome ..
  66. FLUORESCENT AND LARGE METAL CLUSTER COMBINATION PROBES
    Richard Powell; Fiscal Year: 1999
    ..Several new probes are proposed for the development during Phase I: 1) large platinum and palladium cluster complexes (1.8-3...
  67. GLUCOCORTICOIDS & VITAMIN D: ROLE IN ANTI-TUMOR EFFECTS
    Candace Johnson; Fiscal Year: 2009
    ..Also, calcitriol significantly enhances the in vitro and in vivo antitumor efficacy of platinum analogues and taxanes...
  68. GLUTATHIONE BIOSYSTHESIS AND DRUG RESISTANCE
    R Mulcahy; Fiscal Year: 1999
    ..pathway(s) associated with the elevation of GSH commonly detected in cells resistant to alkylating agents and platinum analogs...
  69. Lung Cancer Chemoradiation: Predictors of Survival
    Xifeng Wu; Fiscal Year: 2009
    ..Drug resistance presents a major obstacle in NSCLC treatment. Platinum agents, specifically cisplatin and carboplatin, are the cornerstones of NSCLC therapy...
  70. Population-Specific Genetic Determinants of Susceptibility to Chemotherapies
    PETER HUGH O apos DONNELL; Fiscal Year: 2009
    ..For example, Asians have significantly higher rates of platinum chemotherapy-related toxicities compared to other populations...
  71. Evaluation of CYP24 as a Target for Enhancing Vitamin D*
    Donald Trump; Fiscal Year: 2006
    ..g. taxanes, platinum analogues, antracenediones)...
  72. Molecular Correlates--Oxaliplatin/5FU/XRT, Esophageal CA
    Lakshmi Pendyala; Fiscal Year: 2002
    ..Moreover, the toxicity profile for cisplatin may be disabling. Oxaliplatin (OXP) a diaminocyclohexane platinum complex has a more manageable toxicity profile...
  73. ANTAGONISTS FOR CIS-PLATINUM NEPHROTOXICITY
    Mark Jones; Fiscal Year: 1990
    ..of dithiocarbamate chelating agents (which we have recently prepared) in controlling the nephrotoxicity of cis-platinum at normal and elevated dosage levels...
  74. CIS-PLATINUM DEVELOPMENTAL OTOTOXICITY
    Kathleen Sie; Fiscal Year: 2000
    Hearing loss is associated with administration of some life-threatening medications. Cis-platinum is an effective anti-neoplastic agent which is more likely to cause hearing loss in children than in adults receiving proportionate doses...